Cargando…

Virological outcomes of antiretroviral therapy in Zomba central prison, Malawi; a cross-sectional study

Introduction: Antiretroviral therapy (ART) outcomes that include viral suppression rates are rarely reported among African prison populations. Prisoners deal with specific challenges concerning adherence to ART. We aimed to describe virological outcomes of ART in a large prison in Malawi. Methods: A...

Descripción completa

Detalles Bibliográficos
Autores principales: Mpawa, Happy, Kwekwesa, Aunex, Amberbir, Alemayehu, Garone, Daniela, Divala, Oscar H., Kawalazira, Gift, van Schoor, Vanessa, Ndindi, Henry, van Oosterhout, Joep J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577730/
https://www.ncbi.nlm.nih.gov/pubmed/28782332
http://dx.doi.org/10.7448/IAS.20.1.21623
_version_ 1783260402717556736
author Mpawa, Happy
Kwekwesa, Aunex
Amberbir, Alemayehu
Garone, Daniela
Divala, Oscar H.
Kawalazira, Gift
van Schoor, Vanessa
Ndindi, Henry
van Oosterhout, Joep J.
author_facet Mpawa, Happy
Kwekwesa, Aunex
Amberbir, Alemayehu
Garone, Daniela
Divala, Oscar H.
Kawalazira, Gift
van Schoor, Vanessa
Ndindi, Henry
van Oosterhout, Joep J.
author_sort Mpawa, Happy
collection PubMed
description Introduction: Antiretroviral therapy (ART) outcomes that include viral suppression rates are rarely reported among African prison populations. Prisoners deal with specific challenges concerning adherence to ART. We aimed to describe virological outcomes of ART in a large prison in Malawi. Methods: A cross-sectional study of ART outcomes was conducted at the Zomba Central Prison HIV clinic, Malawi, following the introduction of routine viral load monitoring. All prisoners on ART for at least 6 months were eligible for a viral load test. Patients with ≥1,000 copies/ml received adherence support for 3 months, after which a second VL sample was taken. Patients with ≥5,000 copies/ml on the second sample had virological failure and started 2nd line ART. We describe demographics and patient characteristics and report prevalence of potential- and documented virological failure. In the potential virological failure rate, those who could not be sampled after 3 months adherence support are included as virological failures. Logistic regression analysis was used to determine factors associated with potential ART failure. Results and discussion: Viral load testing was started at the end of 2014, when 1054 patients had ever registered on ART. Of those, 501 (47.5%) had transferred out to another clinic, 96 (9.1%) had died, 11 defaulted (1.0%) and 3 (0.3%) stopped ART. Of 443 (42.0%) remaining alive in care, an estimated 322 prisoners were on ART >6 months, of whom 262 (81.4%) were sampled. Their median age was 35 years (IQR 31–40) and 257 (98.1%) were male. Self-reported adherence was good in 258 (98.5%). The rate of potential ART failure was 8.0%, documented ART failure was 4.6% and documented HIV suppression 95.0%. No patient characteristics were independently associated with potential ART failure, possibly due to low numbers with this outcome. Conclusions: Good virological suppression rates can be achieved among Malawian prisoners on ART, under challenging circumstances.
format Online
Article
Text
id pubmed-5577730
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-55777302017-09-06 Virological outcomes of antiretroviral therapy in Zomba central prison, Malawi; a cross-sectional study Mpawa, Happy Kwekwesa, Aunex Amberbir, Alemayehu Garone, Daniela Divala, Oscar H. Kawalazira, Gift van Schoor, Vanessa Ndindi, Henry van Oosterhout, Joep J. J Int AIDS Soc Short Report Introduction: Antiretroviral therapy (ART) outcomes that include viral suppression rates are rarely reported among African prison populations. Prisoners deal with specific challenges concerning adherence to ART. We aimed to describe virological outcomes of ART in a large prison in Malawi. Methods: A cross-sectional study of ART outcomes was conducted at the Zomba Central Prison HIV clinic, Malawi, following the introduction of routine viral load monitoring. All prisoners on ART for at least 6 months were eligible for a viral load test. Patients with ≥1,000 copies/ml received adherence support for 3 months, after which a second VL sample was taken. Patients with ≥5,000 copies/ml on the second sample had virological failure and started 2nd line ART. We describe demographics and patient characteristics and report prevalence of potential- and documented virological failure. In the potential virological failure rate, those who could not be sampled after 3 months adherence support are included as virological failures. Logistic regression analysis was used to determine factors associated with potential ART failure. Results and discussion: Viral load testing was started at the end of 2014, when 1054 patients had ever registered on ART. Of those, 501 (47.5%) had transferred out to another clinic, 96 (9.1%) had died, 11 defaulted (1.0%) and 3 (0.3%) stopped ART. Of 443 (42.0%) remaining alive in care, an estimated 322 prisoners were on ART >6 months, of whom 262 (81.4%) were sampled. Their median age was 35 years (IQR 31–40) and 257 (98.1%) were male. Self-reported adherence was good in 258 (98.5%). The rate of potential ART failure was 8.0%, documented ART failure was 4.6% and documented HIV suppression 95.0%. No patient characteristics were independently associated with potential ART failure, possibly due to low numbers with this outcome. Conclusions: Good virological suppression rates can be achieved among Malawian prisoners on ART, under challenging circumstances. Taylor & Francis 2017-08-02 /pmc/articles/PMC5577730/ /pubmed/28782332 http://dx.doi.org/10.7448/IAS.20.1.21623 Text en © 2017 Mpawa H et al; licensee International AIDS Society. http://creativecommons.org/licenses/by/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0 Unported (CC BY 3.0) License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Report
Mpawa, Happy
Kwekwesa, Aunex
Amberbir, Alemayehu
Garone, Daniela
Divala, Oscar H.
Kawalazira, Gift
van Schoor, Vanessa
Ndindi, Henry
van Oosterhout, Joep J.
Virological outcomes of antiretroviral therapy in Zomba central prison, Malawi; a cross-sectional study
title Virological outcomes of antiretroviral therapy in Zomba central prison, Malawi; a cross-sectional study
title_full Virological outcomes of antiretroviral therapy in Zomba central prison, Malawi; a cross-sectional study
title_fullStr Virological outcomes of antiretroviral therapy in Zomba central prison, Malawi; a cross-sectional study
title_full_unstemmed Virological outcomes of antiretroviral therapy in Zomba central prison, Malawi; a cross-sectional study
title_short Virological outcomes of antiretroviral therapy in Zomba central prison, Malawi; a cross-sectional study
title_sort virological outcomes of antiretroviral therapy in zomba central prison, malawi; a cross-sectional study
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577730/
https://www.ncbi.nlm.nih.gov/pubmed/28782332
http://dx.doi.org/10.7448/IAS.20.1.21623
work_keys_str_mv AT mpawahappy virologicaloutcomesofantiretroviraltherapyinzombacentralprisonmalawiacrosssectionalstudy
AT kwekwesaaunex virologicaloutcomesofantiretroviraltherapyinzombacentralprisonmalawiacrosssectionalstudy
AT amberbiralemayehu virologicaloutcomesofantiretroviraltherapyinzombacentralprisonmalawiacrosssectionalstudy
AT garonedaniela virologicaloutcomesofantiretroviraltherapyinzombacentralprisonmalawiacrosssectionalstudy
AT divalaoscarh virologicaloutcomesofantiretroviraltherapyinzombacentralprisonmalawiacrosssectionalstudy
AT kawalaziragift virologicaloutcomesofantiretroviraltherapyinzombacentralprisonmalawiacrosssectionalstudy
AT vanschoorvanessa virologicaloutcomesofantiretroviraltherapyinzombacentralprisonmalawiacrosssectionalstudy
AT ndindihenry virologicaloutcomesofantiretroviraltherapyinzombacentralprisonmalawiacrosssectionalstudy
AT vanoosterhoutjoepj virologicaloutcomesofantiretroviraltherapyinzombacentralprisonmalawiacrosssectionalstudy